Log in

NASDAQ:MBRXMoleculin Biotech Earnings Date, Estimates & History

+0.03 (+2.78 %)
(As of 06/5/2020 04:00 PM ET)
Today's Range
Now: $1.11
50-Day Range
MA: $1.11
52-Week Range
Now: $1.11
Volume3.85 million shs
Average Volume836,210 shs
Market Capitalization$67.04 million
P/E RatioN/A
Dividend YieldN/A


Moleculin Biotech (NASDAQ:MBRX) Earnings Information

Moleculin Biotech last posted its quarterly earnings results on May 11th, 2020. The reported ($0.10) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.10). Moleculin Biotech has generated ($0.32) earnings per share over the last year. Moleculin Biotech has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Friday, August 21st, 2020 based off prior year's report dates.

Moleculin Biotech Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Moleculin Biotech (NASDAQ:MBRX) Earnings Estimates

2020 EPS Consensus Estimate: ($0.48)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20201($0.11)($0.11)($0.11)
Q2 20201($0.12)($0.12)($0.12)
Q3 20201($0.12)($0.12)($0.12)
Q4 20201($0.13)($0.13)($0.13)

Moleculin Biotech (NASDAQ MBRX) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSGAAP EPSRevenue EstimateActual RevenueConference CallDetails
5/11/2020Q1 2020($0.10)($0.10)($0.18)N/A
2/21/2019Q4 2018($0.10)($0.1010)($0.10)N/A
11/13/2018Q3 2018($0.13)($0.08)($0.12)N/A
8/13/2018Q2 2018($0.14)($0.20)($0.20)N/A
5/15/2018Q1 2018($0.14)($0.08)($0.14)N/A
3/28/2018Q4 2017($0.12)($0.17)($0.18)N/A
11/14/2017Q3 2017($0.14)($0.14)N/A
8/14/2017Q2 2017($0.19)$0.05N/A
5/15/2017Q1 2017($0.02)($0.18)N/A
4/3/2017Q4 2016($0.12)($0.12)N/A
8/15/2016Q2 2016($0.11)($0.11)N/A
6/16/2016Q1 2016($0.05)($0.05)N/A
(Earnings results data provided by Zacks Investment Research)
This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.